Sensei Biotherapeutics Bolsa (NASDAQ: SNSE)

Últimas noticias sobre Sensei Biotherapeutics (NASDAQ:SNSE) Bolsa

SENSEI BIOTHERAPEUTICS INC

Sensei Biotherapeutics

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics Inc

Greenridge Global analyst William Gregozeski initiates coverage on MoneyHero (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNY#NASDAQ">MNY</a>) with a Buy rating and announces Price Target of $4.

News

Price Target

Initiation

Analyst Ratings

Greenridge Global Initiates Coverage On MoneyHero with Buy Rating, Announces Price Target of $4

Macro Economic Events

Global

Economics

South Korea Says Will Step Up Trade Negotiations With The US To Win Mutually Beneficial Results And Clear Up Uncertainties Caused By Tariffs

<a href="https://truthsocial.com/@realDonaldTrump/114813842665448662">https://truthsocial.com/@realDonaldTrump/114813842665448662</a>

Macro Notification

Politics

General

President Trump Says U.S. Will Impose 25% Tariff On Tunisia

IPOs

ANPA

Rich Sparkle Holdings Limited Announces Pricing Of 1,250,000 Share IPO At $4/Share

A 26-year-old business owner called recently into Dave Ramsey&#8216;s &#8220;<a href="https://www.youtube.com/watch?v=pmwgeIuflGU">EntreLeadership</a>&#8221; podcast with a tough decision: sell the family business for millions or keep building what his father started.
<h2 class="wp-block-heading">Sell Now Or Build Further?</h2>
Dan co-owns a New York-based restaurant cleaning company with his 65-year-old father, who founded the business and is now ready to retire. The company brings in $4.75 million annually and employs 80 cleaners.
After years of working together, a big competitor has offered to buy them out for $6 million. The offer includes $4.5 million in cash and $1.5 million in rollover equity, along with a leadership role for Dan to run the acquiring company's New York City operations.
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. </a></li>
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
</ul>
Dan said he and his dad would split the proceeds evenly. &#8220;It&#8217;s more money than either of us have ever seen,&#8221; he admitted.
Ramsey told Dan to think beyond the immediate windfall. &#8220;One of the decision-making formulas I use is I get out of the moment and I extrapolate out decades,&#8221; he said. &#8220;When you&#8217;re 56, and you look back on your life, how are you going to feel about the 26-year-old version of you?&#8221;
Dan said he hadn&#8217;t considered that. &#8220;I never really thought that far out into the future.&#8221; He knows that, <a href="https://www.benzinga.com/money/investing">invested properly</a>, that chunk of change could be worth several million more down the road.
Ramsey agreed the math made sense: &#8220;If you put $2 million in your pocket at 26, it&#8217;s not a bad day.&#8221;
Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Become an Investor in This $41.3M Clean Energy Brand Today</a>
Still, he cautioned against chasing a payout just because it looks good on paper. &#8220;I&#8217;ve known people who got hundreds of millions of dollars for selling their business, and the only thing they got other than that was <a href="https://www.benzinga.com/startups/24/08/40256205/in-2021-charlie-munger-told-warren-buffett-it-was-a-mistake-to-sell-apple-shares-will-he-be-right-ag">wishing they didn&#8217;t sell it</a>,&#8221; he said.
He told the story of a man who sold his company for $400 million but later called it &#8220;the dumbest thing I ever did,&#8221; crying because the company lost its soul under new ownership. &#8220;Selling something for a big chunk of change is not always something that is without regret,&#8221; Ramsey added.
But he didn&#8217;t think Dan would fall into that trap. &#8220;This is an excellent exit for [your dad] and an excellent on-ramp for something else for you,&#8221; he said. &#8220;I think you do this.&#8221;
Still, he left listeners with a straightforward reminder: &#8220;Just because you get a pile of money doesn&#8217;t mean automatically we need to do it.&#8221;
Read Next:
<ul class="wp-block-list">
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Image: Shutterstock

Personal Finance

Son Wants To Cash Out On Dad's $6 Million Business. Dave Ramsey Brings Up A Teary Man Who Regretted Selling For $400 Million

Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) has outperformed the market over the past 5 years by 304.48% on an annualized basis producing an average annual return of 318.82%. Currently, Quest Diagnostics has a market capitalization of $19.42 billion. 
Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $1,448,542.88 today based on a price of $173.97 for DGX at the time of writing.
<h3>Quest Diagnostics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751920211_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 85.58% at $1.99</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 44.44% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 25.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 12.09% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 11.11% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 10.59% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed up 7.74% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 7.10% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 5.08% at $0.30</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 4.89% at $0.00</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/AUSAF">Australis Capital</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUSAF#OTC">AUSAF</a>) shares closed down 99.67% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed down 16.67% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 12.23% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 10.65% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 9.71% at $3.45</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 6.53% at $0.50</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Growth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 5.48% at $1.20</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed down 5.44% at $8.51</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 5.23% at $6.24</li>
<li><a href="https://www.benzinga.com/quote/RIV">Rivernorth Opps Fund</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#NYSE">RIV</a>) shares closed down 4.62% at $12.28</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed down 3.96% at $4.43</li>
<li><a href="https://www.benzinga.com/quote/LMLLF">Pharmadrug</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LMLLF#OTC">LMLLF</a>) shares closed down 3.74% at $0.01</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

AUSAF

BBRRF

BLGVF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CVSI

FFNTF

GNLN

KAYS

LMLLF

LVRLF

MGWFF

RSSFF

TGIFF

TLRY

UGRO

XXII

Marijuana Stock Movers For July 7, 2025

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) with a Overweight rating and announces Price Target of $74.

MNPR

Cantor Fitzgerald Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $74

Cantor Fitzgerald analyst Ross Osborn initiates coverage on Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) with a Overweight rating and announces Price Target of $12.

Cantor Fitzgerald Initiates Coverage On Bioventus with Overweight Rating, Announces Price Target of $12

Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) reported quarterly losses of $(0.12) per share. This is a 100 percent decrease over losses of $(0.06) per share from the same period last year. The company reported $2.29 million in sales this quarter. This is a 208.21 percent increase over sales of $742.99 thousand the same period last year.

Earnings

LASE

Laser Photonics Q1 EPS $(0.12) Down From $(0.06) YoY, Sales $2.29M Up From $742.99K YoY

Under the terms of the merger agreement, 80% of Presence's common shares will be converted into Norwood Financial common stock while the remaining 20% will be exchanged for cash. Presence's shareholders will have the option to elect to receive either 0.7850 shares of Norwood Financial common stock or $19.75 in cash for each common share of Presence they own. The election is subject to proration to ensure that, in the aggregate, 80% of the transaction consideration will be paid in the form of Norwood Financial common stock. All options to purchase Presence's common stock will be cashed out upon completion of the merger. Based on the closing price $26.65 for Norwood Financial Common Stock on July 3, 2025, the transaction would have an aggregate value of approximately $54.9 million. The purchase price reflects a multiple of 106.6% of Presence's March 31, 2025, tangible book value and a 2.3% core deposit premium. Following completion of the transaction, Presence shareholders who elect to receive common stock share consideration will receive a quarterly cash dividend equal to approximately $0.24 per Norwood Financial share of common stock based on Norwood Financial's current quarterly dividend of $0.31 per share of common stock. This dividend reflects a yield of 3.6% based on Norwood Financial's closing price of $26.65 on July 3, 2025.

NWFL

PBBK

Norwood Financial And PB Bankshares Approve An Agreement And Plan Of Merger Pursuant To Which Presence Will Merge With And Into Norwood; 80% Of Presence's Common Shares Will Be Converted Into Norwood Financial Common Stock While The Remaining 20% Will Be Exchanged For Cash; The Transaction To Have An Aggregate Value Of ~$54.9M

The U.S. dollar is notching its strongest one-day gain against the Japanese yen in nearly two months as traders react to President Donald Trump's sweeping new tariffs targeting <a href="https://www.benzinga.com/markets/equities/25/07/46281204/wall-street-today-trump-tariffs-japan-south-korea-stocks-drop">multiple U.S. trading partners.</a>
Starting Aug. 1, all goods imported from Japan and other Asian trading partners will face a 25% tariff, Trump announced Monday, citing persistent trade imbalances and unfair practices.
The move follows a 90-day pause for negotiations that fell short of providing a better outcome than the &#8220;Liberation Day&#8221; duties on April 2. And now, the fallout is landing hard.
The dollar surged past 146 yen, gaining 1.2% on the day—its sharpest move since May 12. 
<h3 class="wp-block-heading">Markets Shake As White House Sends Tariff Letters To Trading Partners</h3>
In an official letter to Japanese Prime Minister Fumio Kishida, Trump stated that the new tariffs aim to address what he called "years of Japan&#8217;s tariff and non-tariff policies and trade barriers."
He also warned that any retaliatory tariffs would be met with proportional increases by the U.S. and said transshipped goods would face higher rates. 
He also offered an out: Japanese companies that move production to the U.S. won't face tariffs — and he promised quick approvals for those who do.
According to International Trade Statistics data, U.S. imports from Japan totaled $152.07 billion in 2024, with vehicles accounting for $51.27 billion and machinery, including nuclear reactors and boilers, adding another $36.05 billion.
The White House stated that the tariff levels could be revised based on bilateral trade relationships, with the goal of reducing trade deficits and protecting U.S. national security.
<h3 class="wp-block-heading">More Countries Face Tariff Hikes</h3>
South Korea will also face a 25% tariff starting in August under the same terms as Japan. The dollar gained 0.9% against the Korean won in the session, reinforcing the greenback's strength amid heightened global tensions.
Several other countries were also named in the tariff list, including:
<ul class="wp-block-list">
<li>Malaysia: 25% tariff</li>
<li>South Africa: 30% tariff;</li>
<li>Kazakhstan: 25% tariff,</li>
<li>Laos and Myanmar: 40% tariffs</li>
</ul>
<h3 class="wp-block-heading">ETFs Took A Beating</h3>
Country-focused ETFs sold off hard on Monday: 
<ul class="wp-block-list">
<li>The iShares MSCI Japan ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWJ#NYSE">EWJ</a>) dropped 2.3%, marking its worst session since April 10. That's a sharp reversal after a 25% rally off spring lows.</li>
<li>The iShares MSCI South Korea ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWY#NYSE">EWY</a>) plunged 3.5%, also its worst day since early April.</li>
<li>The iShares MSCI Malaysia ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWM#NYSE">EWM</a>) fell 2%.</li>
<li>The iShares MSCI South Africa ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EZA#NYSE">EZA</a>) dropped 2%.</li>
</ul>
<h3 class="wp-block-heading">What's Next?</h3>
The White House said tariffs could still be adjusted — higher or lower — depending on "the strength of the relationship" with each country.
Investors are now watching closely to see how Japan, South Korea, and others respond — and whether the European Union, facing a similar deadline this week, becomes the next target in Trump's escalating trade war.
Meanwhile, the message from markets is clear: tariffs are back in play, and traders are bracing for more volatility ahead.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/07/46280221/vice-stocks-beat-esg-trump-2025">Guns, Booze, And Gambling Stocks Are Crushing ESG In Trump&#8217;s America</a></li>
</ul>
Photo: Shutterstock

Asia

Equities

Government

Regulations

Emerging Markets

Emerging Market ETFs

Econ #s

ETFs

Trump's Surprise Tariffs Just Crushed Japan's Stocks, Yen And More

BTIG analyst Justin Zelin maintains Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) with a Buy and lowers the price target from $64 to $20.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

BTIG Maintains Buy on Jasper Therapeutics, Lowers Price Target to $20

WIIM

NDRA

ENDRA Life Sciences shares are trading higher after the company announced it will be granted a US patent titled "Radio Frequency Applicator".

<a href="https://x.com/PatentAlerts4/status/1942312161243718143" title="https://x.com/PatentAlerts4/status/1942312161243718143">https://x.com/PatentAlerts4/status/1942312161243718143</a>

Biotech

ENDRA Life Sciences To Be Granted US Patent 'Radio Frequency Applicator.'

NBTX

NANOBIOTIX Announces Announces European Health Authorities Agreed To Formally Reclassify NBTXR3 From A Medical Device To A Drug

Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares are trading lower Monday afternoon as markets react to new global trade restrictions announced by the White House. President Donald Trump imposed sweeping 25% tariffs on all goods imported from Japan and South Korea, set to begin Aug. 1.
What To Know: The broad-based duties, which come after a 90-day negotiation period <a href="https://www.benzinga.com/markets/equities/25/07/46281204/wall-street-today-trump-tariffs-japan-south-korea-stocks-drop">expired</a> without a resolution, add to existing tariffs and aim to correct &#8220;unsustainable trade deficits.&#8221;
In official letters, the administration noted the 25% rate was a &#8220;moderate&#8221; measure. The news sent a chill through markets, impacting multinational corporations like Intel that rely on complex global supply chains.
Adding to investor concerns, the administration is <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46282961/super-micro-shares-are-trading-lower-monday-whats-going-on">reportedly preparing</a> to restrict shipments of advanced AI chips to Malaysia and Thailand to prevent the technology from reaching China. 
As a result, the potential for new export licenses and controls on high-performance semiconductors casts a shadow over the entire industry. These dual threats of broad tariffs and specific chip curbs, combined with a looming tariff deadline with the European Union, are weighing heavily on sentiment for major U.S. chipmakers.
Benzinga Edge Rankings: According to <a href="http://benzinga.grsm.io/register174">Benzinga&#8217;s Edge</a> stock rankings, Intel presents a profile that may appeal strongly to value-oriented investors. The stock earns a high value score of 74.75, suggesting it could be trading at a discount relative to its intrinsic worth or industry peers.
However, this strength is contrasted by significant weakness in other key areas. Intel scores poorly on Momentum at 26.55 and receives a very low mark for Growth at 19.18. A ranking for the stock&#8217;s Quality was not available. This data indicates that while Intel may represent a bargain.
INTC Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Intel shares closed Monday down 2.18% to $22. The stock has a 52-week high of $37.16 and a 52-week low of $17.66.
<h2 class="wp-block-heading">How To Buy INTC Stock</h2>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Intel&#8217;s case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Read Also: • <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46282961/super-micro-shares-are-trading-lower-monday-whats-going-on">Super Micro Shares Are Trading Lower Monday: What&#8217;s Going On?</a>
Image: Shutterstock

Tech

INTC

Intel Shares Tumble On Sweeping Tariffs, AI Chip Curbs

Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) has outperformed the market over the past 5 years by 44.98% on an annualized basis producing an average annual return of 59.32%. Currently, Vistra has a market capitalization of $65.73 billion. 
Buying $100 In VST: If an investor had bought $100 of VST stock 5 years ago, it would be worth $1,019.47 today based on a price of $193.70 for VST at the time of writing.
<h3>Vistra's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751919311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Vistra 5 Years Ago Would Be Worth This Much Today

Benchmark analyst David Williams maintains IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and raises the price target from $50 to $55.

IONQ

Benchmark Maintains Buy on IonQ, Raises Price Target to $55

Guidance

MMSI

Merit Medical Sees Prelim. Q2 Revenue $380M-$384M

Press Releases

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Health Care

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Comments

Sensei Biotherapeutics

Noticias

Últimas noticias sobre Sensei Biotherapeutics (NASDAQ:SNSE) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL